Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 14/20 | 0.79 |
| ▸ | SCN3A | Q9NY46 | 8/20 | 0.79 |
| ▸ | SCN1A | P35498 | 1/20 | 0.79 |
| ▸ | SCN4A | P35499 | 1/20 | 0.79 |
| ▸ | SCN7A | Q01118 | 1/20 | 0.79 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.79 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.79 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.79 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.79 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.79 |
| ▸ | MAOB | P27338 | 4/20 | 0.78 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.78 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.78 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.78 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.50 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.50 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.50 |
| ▸ | KDM1A | O60341 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13320297 | 1.00 | KCNH2 (0.79) | KCNH2SCN3ASCN1ASCN4ASCN7A | |
| SCHEMBL862451 | 1.00 | KCNH2 (0.79) | KCNH2SCN3ASCN1ASCN4ASCN7A | |
| SCHEMBL10080247 | 0.89 | KCNH2 (0.81) | KCNH2SCN3ASCN1ASCN4ASCN7A | |
| SCHEMBL2713491 | 0.89 | KCNH2 (0.81) | KCNH2SCN3ASCN1ASCN4ASCN7A | |
| SCHEMBL24491210 | 0.89 | KCNH2 (0.78) | KCNH2SCN3ASCN1ASCN4ASCN7A | |
| SCHEMBL310294 | 0.89 | KCNH2 (0.78) | KCNH2SCN3ASCN1ASCN4ASCN7A | |
| SCHEMBL22546620 | 0.89 | KCNH2 (0.78) | KCNH2SCN3ASCN1ASCN4ASCN7A | |
| SCHEMBL862470 | 0.89 | KCNH2 (0.78) | KCNH2SCN3ASCN1ASCN4ASCN7A | |
| SCHEMBL29685919 | 0.89 | KCNH2 (0.78) | KCNH2SCN3ASCN1ASCN4ASCN7A | |
| Vixotrigine SCHEMBL2831660 | 0.88 | KCNH2 (1.00) | KCNH2SCN3ASCN1ASCN4ASCN7A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143306-B2 | Methods of treating bipolar disorders | Convergence Pharmaceuticals Limited (GB) | 2012-03-27 | — | — | US | disclosed |
| US-20110098335-A1 | NOVEL COMPOUNDS | Convergence Pharmaceuticals Limited (GB) | 2011-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098335-A1 | NOVEL COMPOUNDS | SCN1A, SCN1B, SCNN1B | KCNH2 65/4885SCN3A 8/4885SCN1A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.